# The Study of CM326 in Moderate-to-severe Atopic Dermatitis

> **NCT05671432** · PHASE2 · UNKNOWN · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 240 (estimated)

## Conditions studied

- Moderate-to-severe Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** CM326
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05671432
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-27
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05671432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05671432, "The Study of CM326 in Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05671432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*